Ideaya picks cancer drug candidate, targets human trial application in 2027
10 Articles
10 Articles
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of…
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors - PressReach
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA’s proprietary Phase 1 PRMT5 inhibitor IDE892 CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of all solid tumors, including ~70% of pancreatic cancer IDE101’s preclinical profile, including combination results … Continue reading "IDEAYA…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium











